(Q24244270)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

0 references

1 reference

title

Interventions for latent autoimmune diabetes (LADA) in adults (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Huw Brunt

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

H Davies

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

S Mannan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

R Williams

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

18 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

2 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

CD006165

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Multicenter prevention trial of slowly progressive type 1 diabetes with small dose of insulin (the Tokyo study): preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Effects of a short prednisone regime at clinical onset of type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Complete long-term recovery of beta-cell function in autoimmune type 1 diabetes after insulin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment. A cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Peptide-based treatment for autoimmune diseases: learning how to handle a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Non-obese adult onset diabetes with oral hypoglycemic agent failure: islet cell autoantibodies or reversible beta cell refractoriness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Diabetes Antibody Standardization Program: First Assay Proficiency Evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

The case of the misleading funnel plot

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Forest plots: trying to see the wood and the trees

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Latent autoimmune diabetes of adulthood. Unique features that distinguish it from types 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Latent autoimmune diabetes in adults (LADA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Etiological investigation of diabetes in young adults presenting with apparent type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or type 1.5 diabetes).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

The preliminary report from the nation-wide prevention study for type 1 diabetes initially diagnosed as type 2 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Latent autoimmune diabetes in adults: a guide for the perplexed

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Intensive therapy in adult insulin-dependent diabetes mellitus is associated with improved insulin sensitivity and reserve: a randomized, controlled, prospective study over 5 years in newly diagnosed patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Prednisone administration in recent onset type I diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Beta cell rest and recovery--does it bring patients with latent autoimmune diabetes in adults to euglycemia?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006165.PUB2

7 January 2021

10.1002/14651858.CD006165.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17636829%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference